CD4 and breast cancer: Ruxolitinib increased the cell-type specific error rate in several cell types beyond those observed in BC samples, including classical monocytes, memory and naïve B cells, and CD8 + T cells, with the notable exception of Naïve CD4 + T cells, which showed a drastic decrease in signal fidelity but no change in error rate.